Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges

• Published in: Drug delivery Vol. 29; no. 1; pp. 1142 - 1149
• Main Authors: Li, Shangyong, Zhang, Hui, Chen, Kaiwei, Jin, Mengfei, Vu, Son Hai, Jung, Samil, He, Ningning, Zheng, Zhou, Lee, Myeong-Sok
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2022; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Administration, Oral; Alginates; Biocompatibility; Cancer therapies; Chitosan; chitosan/alginate nanoparticle; Colitis, Ulcerative - drug therapy; colon cancer; Colorectal cancer; Disease; Drug Carriers - therapeutic use; Drug Delivery Systems; Drugs; Efficiency; Environmental science; Fecal incontinence; Humans; Inflammatory bowel disease; Insulin; Laboratories; Methods; Nanoparticles; Oceanography; Oral drug delivery; Particle size; Pharmaceutical Preparations; Polymers; ulcerative colitis; Oral drug delivery; ulcerative colitis; insulin; chitosan/alginate nanoparticle; colon cancer
• ISSN: 1071-7544; 1521-0464; 1521-0464
• DOI: 10.1080/10717544.2022.2058646

Oral drug delivery systems (ODDSs) have various advantages of simple operation and few side effects. ODDSs are highly desirable for colon-targeted therapy (e.g. ulcerative colitis and colorectal cancer), as they improve therapeutic efficiency and reduce systemic toxicity. Chitosan/alginate nanoparticles (CANPs) show strong electrostatic interaction between the carboxyl group of alginates and the amino group of chitosan which leads to shrinkage and gel formation at low pH, thereby protecting the drugs from the gastrointestinal tract (GIT) and aggressive gastric environment. Meanwhile, CANPs as biocompatible polymer, show intestinal mucosal adhesion, which could extend the retention time of drugs on inflammatory sites. Recently, CANPs have attracted increasing interest as colon-targeted oral drug delivery system for intestinal diseases. The purpose of this review is to summarize the application and treatment of CANPs in intestinal diseases and insulin delivery. And then provide a future perspective of the potential and development direction of CANPs as colon-targeted ODDSs.